in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

The INTerpath-009 trial will investigate an individualized neoantigen therapy plus Keytruda in patients with non-small cell lung cancer post-surgery whose disease didn't fully respond to prior ...

NEW YORK – Moderna and Merck will test their personalized neoantigen cancer vaccine V940 with Merck's checkpoint inhibitor Keytruda (pembrolizumab) in certain non-small cell lung cancer patients in a ...

After the infusion, Keytruda binds to the proteins, thereby activating the immune system that overpowers cancer cells, leading the tumours to shrink. It nudges the body’s inherent defence mechanism to ...

Patients were randomized (1:1) to receive either: Keytruda (200 mg IV) Q3W for five cycles concurrent with cisplatin (40 mg/m 2 IV) weekly for five cycles (an optional sixth infusion could be ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Though she’s undergone chemotherapy and radiation, she still needs an infusion of the costly immunotherapy medication Keytruda every six weeks to give her the best chance of survival.

Though she’s undergone chemotherapy and radiation, she still needs an infusion of the costly immunotherapy medication Keytruda every six weeks to give her the best chance of survival. For her, the ...